2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009. In 2009, companies like Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Dendreon Corp. (NASDAQ: DNDN), and Human Genome Sciences, Inc. (NASDAQ: HGSI) led the 2009 pack with exponential returns that were 500% and higher. At BioHealthInvestor.com, we have tracked many of the exponential winners for 2010 with outlooks into 2011. Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) is our sole repeat performer in 2010. Others include ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Amarin Corporation plc (NASDAQ: AMRN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Theravance Inc. (NASDAQ: THRX).
Many companies were screened out because performance has faltered or because of limited history. Read the full lists below at BioHealthInvestor.com:
- Outlook 2011: ARIA, CHTP, CYCC, ENMD, EXAS, EXEL, FOLD, IDIX
- Outlook 2011, Part II: AMRN, ILMN, INHX, JAZZ, NBIX, NPSP, THRX, VPHM
Stocks covered above in detail at BioHealthInvestor.com are ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), EntreMed Inc. (NASDAQ: ENMD), Exact Sciences Corporation (NASDAQ: EXAS), Exelixis, Inc. (NASDAQ: EXEL), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Amarin Corporation plc (NASDAQ: AMRN), Illumina Inc. (NASDAQ: ILMN), Inhibitex Inc. (NASDAQ: INHX), Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Neurocrine Biosciences Inc. (NASDAQ: NBIX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM).
You can also see the same sort of search from 2009 for the 2010 outlook that was done at BioHealthInvestor.com.
JON C. OGG
Top Gaining Stocks
Top Losing Stocks